The popular WestRock Dosepak® and Gold Standard IMC CertiScan® have worked well for Clinical Research; we have proven that with hundreds of thousands of co-packaged Med-ic/Dosepak clinical trials blisters, marketed as the original Cerepak™ smart adherence blister solution since 2011.
*Dosepak® is a registered TM of Westrock. Med-ic® and CerePak® (in Canada) are registered TM of Inteligent Devices.
Inappropriate medication use is widespread in clinical research. This can harm individual participant outcomes, jeopardize trial outcomes, and cause hidden errors that are only discovered post market or after publishing (such as a poorly titrated dosage or undiscovered side effect).
Our solutions make it easy to detect and treat these harmful issues. Many protective features are automatic, such as mobile reminders, misuse alerts, targeted coaching.Shorter trials that reach their endpoints more quickly can gain weeks or months of additional patent protection. This can amount to substantial additional revenue.
Our solutions help studies reach last dose, last participant sooner.Clinical trials are becoming increasingly complex and expensive. Certain activities in a protocol seem straightforward on paper, but in practice can translate into dozens of hours of site work.
Use our solutions to help eliminate needless overhead and streamline processes.New, technology-first strategies are transforming clinical trials. DCTs, participant diversity initiatives, and AI tools are changing from “nice-to-haves” into “must-haves”.
Our solutions are modern tools for modern trials that can help researchers and other stakeholders gain and maintain an advantage.Our industry leading CertiScan® Adherence Platform unlocks the value of your adherence data. CertiScan® handles data retrieval, storage, analysis, and reporting.
CertiScan® is a full suite that includes web portals, desktop software, mobile apps, developer tools, and a unifying cloud backend. You can use the entire platform as a whole, or a just subset that satisfies your particular needs.
Background: Non-adherence to prescription medications is exhibited by approximately 50% of patients and is…
Read More
PRESS RELEASE May 6, 2024 – New York, NY — Information Mediary Corp (IMC)…
Read More